Comparative Efficacy of GLP-1 Receptor Agonists, Exercise, and Their Combination on Body Composition and Glucolipid Metabolism in Adults With Overweight or Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
Obes RevJul 13, 2026 (epub)
Matteo Vandoni, Alessandro Gatti, Virginia Rossi et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the effects of GLP-1 receptor agonists, structured exercise, and their combination on body composition and glucolipid metabolism in adults with overweight or obesity. Among 1009 participants, the combination therapy showed the most significant reductions in weight (SMD -1.04) and fat mass (SMD -1.01) compared to placebo, indicating superior efficacy over monotherapies.
Key findings
- Combination therapy resulted in a significant weight reduction (SMD -1.04; 95% CI -1.24 to -0.83) compared to placebo.
- Fat mass decreased significantly with combination therapy (SMD -1.01; 95% CI -1.27 to -0.75).
- Waist-to-hip ratio improved significantly with combination therapy (SMD -0.55; 95% CI -0.91 to -0.18).
- HDL-C levels increased with combination therapy (SMD 0.32; 95% CI 0.04 to 0.61) compared to placebo.
Why it matters
The findings suggest that combining GLP-1 receptor agonists with structured exercise may provide enhanced benefits for weight management and metabolic health in adults with obesity, which is crucial for reducing obesity-related complications.